Advanced Drug Delivery Systems for Colonic Disorders

Advanced Drug Delivery Systems for Colonic Disorders presents state-of-the-art methods for targeted drug delivery to the colon. These methods can prolong drug half-lives, improve bioavailability, optimize pharmacokinetics, and reduce medication dosing frequency. Chapters allow readers to not only become familiar with advancements, but also understand concepts by providing illustrations, figures, and informative tables. Contents cover an overview of colonic diseases, the cellular and molecular mechanisms involved, current and traditional therapeutic approaches, biomaterials, oral drug delivery methods, targeted drug delivery, nutraceuticals and herbal medicine approaches, prebiotics, probiotics and symbiotics, nanomedicine approaches, and the status of clinical trials. This book is the perfect resources for researchers in pharma, biomaterials, and nutrition to help familiarize them with new and upcoming therapeutic methods. Research physicians in GI can also benefit from reading this book for its clinical applications.

• Covers recent perspectives and challenges towards the treatment of colonic disorders
• Provides insights into how advanced drug delivery systems can be effectively used for the management of various types of colonic disorders
• Discusses drug delivery strategies to manage inflammatory bowel disease (chronic inflammation in the digestive tract), ulcerative colitis (inflammation and ulcers in colon), Crohn's disease, Colonic polyps, Shigellosis, Colon Bleeding or Hemorrhage, Diverticulosis and colon cancer

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.

Dr. Raimar Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany and PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.

Dr. Sachin Kumar Singh, is working as professor and head of Pharmaceutical Chemistry and Quality Assurance at School of Pharmaceutical Sciences, Lovely Professional University, India. He is an honorary professor at Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, University of Technology Sydney, Australia and School of Medical and Life Sciences, Sunway University, 47500 Sunway City, Malaysia. He has 14 years of teaching and research experience. Dr. Singh has completed one DST-SERB funded project on development of SNEDDS of Polypeptide-k for treatment of diabetes mellitus. He has published 500 plus research papers with cumulative impact of 1500 plus, authored 5 books and 25 book chapters. He has 10 granted patents to his credit. He is expert in development of novel drug delivery systems, synbiotics based formulations, analytical and bioanalytical method development and BA-BE studies. He has graduated 17 PhD students and 35 M Pharmacy students and currently graduating 3 masters and 6 PhD students. He is also featured under top 2% scientists of world as per the list of 2021, 2022 and 2023, published by Stanford University, USA. Currently his “h” index is 48 with 11000 plus citations. He is a recipient various national awards including Dr. B.C. Deb memorial award for popularization of science-2020 (honoured by Indian Science Congress Association), Bharat Shiksha Ratan Award-2014 (by Global Society for Health and Educational Growth, Delhi, India) and Bharat Gaurav Puraskar-2022 (by KTK outstanding achievers and education foundation, New Delhi) and Distinguished Alumnus Award (by Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka).

Muralikrishnan Dhanasekaran, is a Professor of Pharmacology and Toxicology at the Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University. He earned his Ph.D. in 1999 from the Jadavpur University, India, in neuropharmacology. From 1999-2001, he became a post-doctoral fellow at the University of Nebraska Medical Center, Omaha, Nebraska, and the Uni-versity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND. He served as a re-search instructor of pharmacology at Texas A & M Health Sciences, Temple, TX. His major area of teaching and research is related to pathophysiology, pharmacology, and toxicology in dementia, movement disorders, addiction (substances of abuse-designer drugs, nicotine, alcohol), hyperglycemia, epilepsy, and aging. His research was funded by the Alzheimer’s Association and Pharmaceutical com-panies in the USA. He has over one hundred and thirteen peer-reviewed publications, fifty book chap-ters, and around four hundred abstracts in national and international meetings in the area of pharma-cology, toxicology, and natural bioactives. He has received several awards for teaching, service, and outreach. He has been an editor or on the editorial board for several books and journals including nat-ural products, pharmacology, toxicology, and neuropharmacology.

Kamal Dua is a Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2026, 2025 and 2024 in Research Magazine by “The Australian” in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2026, 2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.